ATNAA

D Number 6 dated May 2, 2019. ----------------------------------------------------- The Defense Logistics Agency Troop Support is seeking sources capable of providing the Antidote Treatment Nerve Agent Auto-Injector (ATNAA). The ATNAA shall be licensed by the Food and Drug Administration (FDA). Each auto-injector shall deliver 2.1 mg of atropine and 600mg of pralidoxime chloride in separate chambers, and be suitable for intramuscular administration. Must have FDA approval to sell the ATNAA. If your firm currently manufactures or distributes the ATNAA, please provide information with respect to the following: a) Place of manufacture b) Estimated annual capacity c) FDA registration d) Product name and description including description of any special features e) Current unit sale price f) Estimated inventory level and storage requirements *** NEW PRODUCTS UNDER DEVELOPMENT*** For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the ATNAA or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically via emailed to Jessica De La Hoz, Contracting Officer, Phone: 445-737-3623, Email: Jessica.DeLaHoz@dla.mil